Covered recipient · General Payments record
MILAN R SHETH
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$11,397.78
60 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,560.00 | 5 |
| Food and Beverage | $1,353.74 | 51 |
| Education | $274.89 | 3 |
| Travel and Lodging | $209.15 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $3,850.00 | 2 |
| AstraZeneca Pharmaceuticals LP | $2,611.49 | 5 |
| ADC Therapeutics America, Inc. | $2,400.00 | 1 |
| Janssen Scientific Affairs, LLC | $1,090.00 | 1 |
| Janssen Biotech, Inc. | $442.60 | 16 |
| Merck Sharp & Dohme LLC | $151.13 | 7 |
| Bayer Healthcare Pharmaceuticals Inc. | $119.92 | 1 |
| Genentech USA, Inc. | $110.91 | 4 |
| Celgene Corporation | $101.14 | 4 |
| Incyte Corporation | $99.99 | 1 |
| SANOFI-AVENTIS U.S. LLC | $74.95 | 1 |
| Rigel Pharmaceuticals, Inc. | $70.87 | 3 |
| Amgen Inc. | $69.41 | 4 |
| Lilly USA, LLC | $44.46 | 2 |
| Dendreon Pharmaceuticals LLC | $31.83 | 2 |
| Pharmacyclics LLC, An AbbVie Company | $28.20 | 1 |
| PFIZER INC. | $24.76 | 1 |
| Novartis Pharmaceuticals Corporation | $22.32 | 1 |
| Ipsen Biopharmaceuticals, Inc | $21.53 | 1 |
| Puma Biotechnology, Inc. | $17.50 | 1 |
| E.R. Squibb & Sons, L.L.C. | $14.77 | 1 |
Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MILAN R SHETH
NPI 1235217266 · CMS profile ID 192416
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LONG BEACH, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1235217266?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MILAN R SHETH, NPI 1235217266, CMS profile ID 192416. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235217266?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MILAN R SHETH, NPI 1235217266, CMS profile ID 192416. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235217266?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MILAN R SHETH, NPI 1235217266, CMS profile ID 192416, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1235217266?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
60 matching records · $11,397.78 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–60 of 60.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $9.70 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048268485 | CMS |
| Celgene Corporation | $16.66 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015268087 | CMS |
| Dendreon Pharmaceuticals LLC | $13.47 | 02/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060290855 | CMS |
| Dendreon Pharmaceuticals LLC | $18.36 | 02/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060290857 | CMS |
| Merck Sharp & Dohme LLC | $20.63 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048268605 | CMS |
| Janssen Biotech, Inc. | $12.00 | 01/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988037499 | CMS |
| Celgene Corporation | $31.27 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015268055 | CMS |
| Janssen Biotech, Inc. | $12.55 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988037533 | CMS |
| Rigel Pharmaceuticals, Inc. | $16.86 | 01/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1033384031 | CMS |
| Merck Sharp & Dohme LLC | $19.05 | 01/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048715055 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $95,311.44 | 26 |
| PY2024 | Principal investigator | $177,788.04 | 45 |
| PY2023 | Principal investigator | $221,292.48 | 25 |
| PY2022 | Recipient | $1,298.00 | 1 |
| PY2022 | Principal investigator | $59,848.17 | 10 |
| PY2021 | Principal investigator | $89,794.51 | 10 |
| PY2020 | Principal investigator | $51,791.31 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
26 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $2,070.00 | 12/22/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175439807 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,380.00 | 11/24/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911837 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,035.00 | 11/24/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911839 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,045.00 | 11/24/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199911841 |
| Principal investigator 1 | Janssen Research & Development, LLC | $42,357.79 | 11/07/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175439795 |
| Principal investigator 1 | ABBVIE INC. | $1,035.00 | 11/04/2025 | Non-covered Recipient Entity SADDLEBACK MEDICAL CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202521237 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,380.00 | 10/27/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide | No dispute reported | 06/30/2026 | 1175439801 |
| Principal investigator 1 | ABBVIE INC. | $3,581.00 | 10/09/2025 | Non-covered Recipient Entity ORANGE COAST MEDICAL CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202516449 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,760.00 | 09/29/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175439772 |
| Principal investigator 1 | Janssen Research & Development, LLC | $172.50 | 09/01/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175439778 |
| Principal investigator 1 | ABBVIE INC. | $414.00 | 08/28/2025 | Non-covered Recipient Entity LONG BEACH MEMORIAL MEDICAL CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202506513 |
| Principal investigator 1 | Janssen Research & Development, LLC | $172.50 | 08/22/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175439767 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 08/05/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202502216 |
| Principal investigator 1 | ABBVIE INC. | $1,035.00 | 08/05/2025 | Non-covered Recipient Entity LONG BEACH MEMORIAL MEDICAL CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202502218 |
| Principal investigator 1 | ABBVIE INC. | $2,561.00 | 08/05/2025 | Non-covered Recipient Entity ORANGE COAST MEDICAL CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202502220 |
| Principal investigator 1 | ABBVIE INC. | $4,416.00 | 07/29/2025 | Non-covered Recipient Entity LONG BEACH MEMORIAL MEDICAL CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202500412 |
| Principal investigator 1 | ABBVIE INC. | $414.00 | 06/03/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202489881 |
| Principal investigator 1 | ABBVIE INC. | $1,035.00 | 06/03/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202489883 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,900.00 | 05/19/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175439784 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 05/19/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther | No dispute reported | 06/30/2026 | 1175439789 |
| Principal investigator 1 | ABBVIE INC. | $2,054.00 | 05/15/2025 | Non-covered Recipient Entity ORANGE COAST MEDICAL CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202485009 |
| Principal investigator 1 | ABBVIE INC. | $3,325.05 | 05/07/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202482825 |
| Principal investigator 1 | ABBVIE INC. | $5,865.00 | 04/24/2025 | Non-covered Recipient Entity MEMORIAL HEALTH SERVICES | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202479374 |
| Principal investigator 1 | ABBVIE INC. | $2,054.00 | 04/03/2025 | Non-covered Recipient Entity ORANGE COAST MEDICAL CENTER | A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma | No dispute reported | 06/30/2026 | 1202474311 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,029.60 | 01/23/2025 | Non-covered Recipient Entity Memorialcare Med Group | Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study | No dispute reported | 06/30/2026 | 1175169911 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,450.00 | 01/17/2025 | Non-covered Recipient Entity Memorialcare Med Group | Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study | No dispute reported | 06/30/2026 | 1175170079 |